Meridian rapid colitis test:
This article was originally published in Clinica
The US FDA has cleared for sale Meridian Bioscience's rapid new test for diagnosing a major cause of antibiotic-associated colitis. The ImmunoCard Toxins A&B test detects the most important toxins produced by strains of the Clostridium difficile bacterium. By producing a colour-change result in just minutes, the test allows for a rapid "test and treat" response following symptoms, said the Cincinnati, Ohio firm.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.